Mediaspace scheduled maintenance: Aug 25, 2026 07:00 - 12:00 AM. During this time, videos will be temporarily unavailable. Check status updates.

Home

Person

Sylvie Hauert

This person has left EPFL

About
Privacy
Disclaimer

Graph Chatbot

Related publications (4)

Page 1 of 1

Development of a nano-adjuvant cancer vaccine and its evaluation for melanoma in combination with radiotherapy

Sylvie Hauert

Cancer is the second leading cause of death in the world and melanoma is the deadliest type of skin cancer. Although surgery, radiotherapy and chemotherapy are still standard treatments, the discovery of the role played by the immune system in cancer has a ...

EPFL2018

Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice

Melody Swartz, Douglas Hanahan, Mélanie Louise Tichet, Stephan Wullschleger, Gabriele Galliverti, Sylvie Hauert

Treatment of patients bearing human papillomavirus (HPV)-related cancers with synthetic long-peptide (SLP) therapeutic vaccines has shown promising results in clinical trials against premalignant lesions, whereas responses against later stage carcinomas ha ...

AMER ASSOC CANCER RESEARCH2018

Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma

Melody Swartz, Douglas Hanahan, Krisztian Homicsko, Laura Jeanbart, Lambert Charles François Potin, Marcela Rincón-Restrepo, Manuel Andreas Fankhauser, Sylvie Hauert, Christopher Claude Giuseppe Tremblay

In melanoma, vascular endothelial growth factor-C (VEGF-C) expression and consequent lymphangiogenesis correlate with metastasis and poor prognosis. VEGF-C also promotes tumor immunosuppression, suggesting that lymphangiogenesis inhibitors may be clinicall ...

Amer Assoc Advancement Science2017

Vaccine nanocarriers: Coupling intracellular pathways and cellular biodistribution to control CD4 vs CD8 T cell responses

Jeffrey Alan Hubbell, Melody Swartz, Sachiko Hirosue, Edward Allen Phelps, Marcela Rincón-Restrepo, Sylvie Hauert

Nanoparticle delivery systems are known to enhance the immune response to soluble antigens (Ags) and are thus a promising tool for the development of new vaccines. Our laboratory has engineered two different nanoparticulate systems in which Ag is either en ...

Elsevier Sci Ltd2017